To counteract this, PEG‐conjugated antibodies or “nanobodies” against EGFR are added onto the exosomal membrane increasing the circulation time and binding to EGFR overexpressing tumour cells (Kooijmans et al., 2016). Here, EGFR is linked to neoplasm.